Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Jenner

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Journal of the American Chemical Society|May 23, 2017
Discovery and Biosynthesis of Gladiolin: A Burkholderia gladioli Antibiotic with Promising Activity against Mycobacterium tuberculosisLijiang Song, Matthew Jenner, Joleen Masschelein, et al.
Insights Into Imaging|July 28, 2022
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myelomaMihaela Rata, Matthew Blackledge, Erica Scurr, et al.
Advances in Therapy|January 21, 2021
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab MonotherapyAjai Chari, Markus Munder, Katja Weisel, et al.
JACS Au|May 1, 2026
PARAS: High-Accuracy Machine Learning of Substrate Specificities in Nonribosomal Peptide SynthetasesBarbara R Terlouw, Chuan Huang, David Meijer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2018
Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic <i>ERCC6L2</i> variantsHemanth Tummala, Arran D Dokal, Amanda Walne, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
Insights Into Imaging|October 15, 2023
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma studySam Keaveney, Alina Dragan, Mihaela Rata, et al.
British Journal of Haematology|November 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myelomaGaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, et al.
British Journal of Haematology|February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Journal of the American Chemical Society|May 23, 2017
Discovery and Biosynthesis of Gladiolin: A Burkholderia gladioli Antibiotic with Promising Activity against Mycobacterium tuberculosisLijiang Song, Matthew Jenner, Joleen Masschelein, et al.
Insights Into Imaging|July 28, 2022
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myelomaMihaela Rata, Matthew Blackledge, Erica Scurr, et al.
Advances in Therapy|January 21, 2021
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab MonotherapyAjai Chari, Markus Munder, Katja Weisel, et al.
JACS Au|May 1, 2026
PARAS: High-Accuracy Machine Learning of Substrate Specificities in Nonribosomal Peptide SynthetasesBarbara R Terlouw, Chuan Huang, David Meijer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2018
Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic <i>ERCC6L2</i> variantsHemanth Tummala, Arran D Dokal, Amanda Walne, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
Insights Into Imaging|October 15, 2023
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma studySam Keaveney, Alina Dragan, Mihaela Rata, et al.
British Journal of Haematology|November 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myelomaGaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, et al.
British Journal of Haematology|February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.
Pageof 8